Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment

Neuropharmacology

Volumn 48, Issue 1, 2005, Pages 34-42

  Dremencov, Eliyahu ^a   Newman, Michael E ^b   Kinor, Noa ^a   Blatman Jan, Gitit ^a   Schindler, Cheryl J ^a   Overstreet, David H ^c   Yadid, Gal ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Desipramine; Flinders Sensitive Line; Microdialysis; Nefazodone; Nucleus accumbens

Indexed keywords

8 [4 (5 AMINO 2,4 DIMETHOXYBENZOYL)BUTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN 2C ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLOOD LEVEL; CORRELATION ANALYSIS; DEPRESSION; DOPAMINE RELEASE; DRUG EFFECT; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DESIPRAMINE; DISEASE MODELS, ANIMAL; DOPAMINE; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; MODELS, ANIMAL; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN; SPIRO COMPOUNDS; STAINING AND LABELING; SULFONAMIDES; TIME FACTORS; TRIAZOLES;

EID: 11144343305     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.09.013     Document Type: Article

References (47)

1. D.W. Bonhaus, K.K. Weinhardt, M. Taylor, A. DeSouza, P.M. McNeeley, K. Szczepanski, D.J. Fontana, J. Trinh, C.L. Rocha, M.W. Dawson, L.A. Flippin, and R.M. Eglen RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist Neuropharmacology 36 1997 621 629
2. L.A. Brotto, L.A. Hanson, and B.B. Gorzalka Nefazodone attenuates the stress-induced facilitation of wet dog shaking behaviour but not the facilitation of sexual behaviour in female rats Eur. J. Pharmacol. 381 1999 101 104
3. F.P. Bymaster, R.K. McNamara, and P.V. Tran New approaches to developing antidepressants by enhancing monoaminergic neurotransmission Expert Opin. Investig. Drugs 12 2003 531 543
4. A.D. Campbell, and W.J. McBride Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens Pharmacol. Biochem. Behav. 51 1995 835 842
5. F. Chen, and A.J. Lawrence The effects of antidepressant treatment on serotonergic and dopaminergic systems in fawn-hooded rats: a quantitative autoradiography study Brain Res. 976 2003 22 29
6. T.I. Cremers, M. Giorgetti, F.J. Bosker, S. Hogg, J. Arnt, A. Mork, G. Honig, K.P. Bogeso, B.H. Westerink, H. Den Boer, H.V. Wikstrom, and L.H. Tecott Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade Neuropsychopharmacology 29 2004 1782 1789
7. R. Davis, R. Whittington, and H.M. Bryson Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression Drugs 53 1997 608 636
8. G. Di Giovanni, V. Di Matteo, and E. Esposito Serotonin/dopamine interaction - focus on 5-HT2C receptor, a new target of psychotropic drugs Indian J. Exp. Biol. 40 2002 1344 1352
9. V. Di Matteo, A. De Blasi, C. Di Giulio, and E. Esposito Role of 5-HT(2C) receptors in the control of central dopamine function Trends Pharmacol. Sci. 22 2001 229 232
10. E. Dremencov, I. Gispan-Herman, M. Rosenstein, A. Mendelman, D.H. Overstreet, J. Zohar, and G. Yadid The serotonin-dopamine interaction is critical for fast-onset action of antidepressant treatment: in vivo studies in an animal model of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 141 147
11. A.S. Eison, M.S. Eison, J.R. Torrente, R.N. Wright, and F.D. Yocca Nefazodone: preclinical pharmacology of a new antidepressant Psychopharmacol. Bull. 26 1990 311 315
12. S. Esteban, J. Llado, A. Sastre-Coll, and J.A. Garcia-Sevilla Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo Naunyn Schmiedebergs Arch. Pharmacol. 360 1999 135 143
13. M. Giorgetti, and L.H. Tecott Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems Eur. J. Pharmacol. 488 2004 1 9
14. A. Gobert, J.M. Rivet, F. Lejeune, A. Newman-Tancredi, A. Adhumeau-Auclair, J.P. Nicolas, L. Cistarelli, C. Melon, and M.J. Millan Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat Synapse 36 2002 205 221
15. R.J. Goldberg Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide Drugs Aging 11 1997 119 131
16. I. Gurevich, H. Tamir, V. Arango, A.J. Dwork, J.J. Mann, and C. Schmauss Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims Neuron 34 2002 349 356
17. L.A. Hanson, B.B. Gorzalka, and L.A. Brotto The antidepressant, nefazodone, attenuates corticosterone-induced increases in 5-HT2A receptor-mediated behaviors in the female rat Eur. J. Pharmacol. 342 1998 163 165
18. J. Hietala, M. Kuonnamaki, E.P. Palvimaki, A. Laakso, H. Majasuo, and E. Syvalahti Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2C receptors after chronic treatment Psychopharmacology (Berl) 157 2001 180 187
19. J. Hyttel Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) Int. Clin. Psychopharmacol. 9 1994 19 26
20. J. Ichikawa, and H.Y. Meltzer R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum J. Pharmacol. Exp. Ther. 291 1999 1227 1232
21. S. Ikemoto, and J. Panksepp The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking Brain Res. Brain Res. Rev. 31 1999 6 41
22. G.A. Kennett, S. Lightowler, V. de Biasi, N.C. Stevens, M.D. Wood, I.F. Tulloch, and T.P. Blackburn Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function Neuropharmacology 33 1994 1581 1588
23. Y. Kitamura, H. Araki, and Y. Gomita Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test Pharmacol. Biochem. Behav. 71 2002 63 69
24. M.L. Kram, G.L. Kramer, P.J. Ronan, M. Steciuk, and F. Petty Dopamine receptors and learned helplessness in the rat: an autoradiographic study Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 639 645
25. J. Labrecque, A. Fargin, M. Bouvier, P. Chidiac, and M. Dennis Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells Mol. Pharmacol. 48 1995 150 159
26. H. Loo, A. Hale, and H. D'Haenen Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study Int. Clin. Psychopharmacol. 17 2002 239 247
27. G. Lucas, and U. Spampinato Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum J. Neurochem. 74 2000 693 701
28. J.H. Meyer, V.S. Goulding, A.A. Wilson, D. Hussey, B.K. Christensen, and S. Houle Bupropion occupancy of the dopamine transporter is low during clinical treatment Psychopharmacology (Berl) 163 2002 102 105
29. J.H. Meyer, S. Kruger, A.A. Wilson, B.K. Christensen, V.S. Goulding, A. Schaffer, C. Minifie, S. Houle, D. Hussey, and S.H. Kennedy Lower dopamine transporter binding potential in striatum during depression Neuroreport 12 2001 4121 4125
30. R. Mongeau, P. Blier, and C. de Montigny The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments Brain Res. Brain Res. Rev. 23 1997 145 195
31. D.H. Overstreet Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists Behav. Genet. 32 2002 335 348
32. D.H. Overstreet, O. Pucilowski, A.H. Rezvani, and D.S. Janowsky Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression Psychopharmacology (Berl) 121 1995 27 37
33. D.H. Overstreet, L.C. Daws, G.D. Schiller, J. Orbach, and D.S. Janowsky Cholinergic/serotonergic interactions in hypothermia: implications for rat models of depression Pharmacol. Biochem. Behav. 59 1998 777 785
34. K. Pacak, O. Tjurmina, M. Palkovits, D.S. Goldstein, C.A. Koch, T. Hoff, and G.P. Chrousos Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study Neuroendocrinology 76 2002 148 157
35. L. Pania, and G.L. Gessab Dopaminergic deficit and mood disorders Int. Clin. Psychopharmacol. 17 Suppl. 4 2002 1 7
36. L.H. Parsons, and J.B. Justice Jr. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis Brain Res. 606 1993 195 199
37. C.G. Pick, D. Paul, M.S. Eison, and G.W. Pasternak Potentiation of opioid analgesia by the antidepressant nefazodone Eur. J. Pharmacol. 211 1992 375 381
38. K. Rickels, E. Schweizer, C. Clary, I. Fox, and C. Weise Nefazodone and imipramine in major depression: a placebo-controlled trial Br. J. Psychiatry 164 1994 802 805
39. P. Rosel, B. Arranz, L. San, J. Vallejo, J.M. Crespo, M. Urretavizcaya, and M.A. Navarro Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims Psychiatry Res. 99 2000 173 181
40. G. Sacchetti, M. Bernini, M. Gobbi, S. Parini, L. Pirona, T. Mennini, and R. Samanin Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors Naunyn Schmiedebergs Arch. Pharmacol. 363 2001 66 72
41. C. Sanchez, and J. Hyttel Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding Cell. Mol. Neurobiol. 19 1999 467 489
42. A. Seretti, P. Artioli, and D. De Ronchi The 5-HT2C receptor as a target for mood disorders Expert Opin. Ther. Targets 8 2004 15 23
43. R. Tao, and S.B. Auerbach Regulation of serotonin release by GABA and excitatory amino acids J. Psychopharmacol. 14 2000 100 113
44. G. Yadid, R. Nakash, I. Deri, G. Tamar, N. Kinor, I. Gispan, and A. Zangen Elucidation of the neurobiology of depression: insights from a novel genetic animal model Prog. Neurobiol. 62 2000 353 378
45. A. Zangen, D.H. Overstreet, and G. Yadid High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment J. Neurochem. 69 1997 2477 2483
46. A. Zangen, D.H. Overstreet, and G. Yadid Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment Brain Res. 824 1999 243 250
47. A. Zangen, R. Nakash, D.H. Overstreet, and G. Yadid Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens Psychopharmacology (Berl) 155 2001 434 439